In light of recent news and misconceptions about Seresto collars, we wanted to assure you of their safety and approval by the EPA.
Elanco CEO Jeff Simmons appeared before the House of Representatives Subcommittee on Economic and Consumer Policy on Wednesday, June 15, to share the facts about Seresto. A resulting USA Today article suggested the product should be removed from the market.
Importantly, there is no evidence in the scientific evaluation conducted for registration purposes or in the regularly reviewed pharmacovigilance data to suggest a recall of Seresto is warranted, nor has one been requested, or even suggested, by any regulatory agency.
The U.S. Environmental Protection Agency is the regulatory body that has jurisdiction over the recall of pesticide products like Seresto. Elanco continues to unequivocally stand behind the safety profile of Seresto. It remains available to consumers in the United States and more than 80 countries around the world as an effective way to protect pets against fleas and ticks that can negatively impact quality of life and even transmit deadly
To reinforce a few key points:
- Seresto was approved by the Environmental Protection Agency based on the results of more than 80 safety, toxicity, and efficacy studies.
- Incident reports are collected and reported without regard to actual causation by the product, providing a raw number starting point which must be further evaluated using an internationally accepted standard method of scientific analysis. Based on those analyses, our pharmacovigilance team has not identified any deaths caused by Seresto’s active ingredients.
- With more than 33 million collars sold in the U.S., incident reports (most of which involve minor or moderate incidents) represent an extremely small proportion of the Seresto collars in use.
- While all products carry some risk of side effects, the risk posed by Seresto is not unreasonable, which is why the American Veterinary Medical Association has opposed canceling Seresto’s EPA registration.
- The benefits of Seresto are significant. It provides eight months of continuous, affordable coverage for families against fleas and ticks, which can carry serious and potentially fatal diseases, like Lyme Disease and Rocky Mountain Spotted Fever. The incidence of these tick-borne diseases is on the rise — CDC estimates approximately 500,000 human cases annually. Seresto offers a much-needed, costeffective option for protecting pets and people.
For more information about Seresto and its safety, click here.
Please feel free to reach out to us if you have any questions at all!